EVAX Evaxion
Price Chart
Executive Summary
Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While this is the second Galien recognition in under a year, it is a non-financial, reputational award that does not change the company's clinical or financial trajectory. The filing contains no revenue, EPS, guidance, or other material financial data.
Actionable Insight
The award provides reputational validation but does not alter Evaxion's clinical or funding timeline. Monitor upcoming clinical data readouts and capital-raising events, as the company's $30M market cap and clinical-stage status imply continued cash needs. No immediate trading catalyst from this release.
Key Facts
- Evaxion awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology.
- This is the second recognition from the Prix Galien Foundation in less than a year (previous award in Dec 2025).
- Evaxion is a clinical-stage TechBio company with no revenue or financial data disclosed in this release.
- The award committee comprised 12 experts who evaluated innovation, clinical application, and utility.
Financial Impact
No financial figures disclosed; the award has no immediate revenue or cash impact.
Risk Factors
- Clinical-stage company with no approved products or disclosed revenue — high cash burn risk.
- Award has no direct impact on pipeline progression or regulatory milestones.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310899 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
6-K
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 12, 2026
3d ago
|
Press Release
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 11, 2026
3d ago
|
6-K
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
May 12, 2026
4w ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 7, 2026
5w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.64 (−10.57%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.64 (−20.35%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access